Roche receives approval from European Commission to use Perjeta in combination with Herceptin and ch...
Roche receives approval from European Commission to use Perjeta in combination with Herceptin and chemotherapy
About this item
Full title
Roche receives approval from European Commission to use Perjeta in combination with Herceptin and chemotherapy
Publisher
London: Normans Media Ltd
Journal title
M2 Pharma, 2015
Language
English
Formats
Publication information
Publisher
London: Normans Media Ltd
Subjects
More information
Scope and Contents
Contents
M2PHARMA-August 4, 2015-Roche receives approval from European Commission to use Perjeta in combination with Herceptin and chemotherapy (C)2015 M2 COMMUNICATIONS http://www.m2.com Roche, a Swiss-based global healthcare company, has received approval from the European Commission to use Perjeta (pertuzum...
Alternative Titles
Full title
Roche receives approval from European Commission to use Perjeta in combination with Herceptin and chemotherapy
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1700917738
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1700917738
How to access this item
Log in as a Library member
